Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.
|Videos|June 29, 2016
Alzheimer Disease and Chromosome Y
Author(s)Bobby Lazzara, MD
In this Medical News Minute, Dr. Bobby Lazzara discusses a recent finding on Alzheimer disease and chromosome Y in men.
Advertisement
In this Medical News Minute, developed exclusively for Neurology Times, Dr. Bobby Lazzara examines a hypothesis that men with a lifetime-acquired loss of chromosome Y are more susceptible to developing Alzheimer disease.
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.
Joanna Wardlaw, MD, Professor of Applied Neuroimaging at the University of Edinburgh, discusses the evolving understanding of cerebral small vessel disease, emerging therapeutic approaches, and the makings behind a successful trial.
Here's some of what is coming soon to NeurologyLive® this week.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS
2
PREVAiLS Phase 3 Trial Evaluates Pridopidine in Early, Rapidly Progressive ALS
3
Analyzing Inebilizumab’s Durable Benefit in MINT Open-Label Extension
4
Sevasemten Misses Primary Endpoint in Pivotal Trial for Becker Muscular Dystrophy
5